Astrana Health (ASTH) Cash & Equivalents (2010 - 2026)

Astrana Health's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $478.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 85.05% year-over-year to $478.4 million; the TTM figure through Mar 2026 stood at $478.4 million (up 85.05% YoY), while the FY2025 annual figure was $429.5 million, up 48.89% from the prior year.
• Cash & Equivalents came in at $478.4 million for Q1 2026 at Astrana Health, up from $429.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $478.4 million in Q1 2026 to a low of $184.0 million in Q3 2022.
• A 5-year average of $314.4 million and a median of $293.8 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents declined 22.78% in 2025 and surged 85.05% in 2026, its largest moves.
• Astrana Health's Cash & Equivalents stood at $288.0 million in 2022, then rose by 2.01% to $293.8 million in 2023, then retreated by 1.82% to $288.5 million in 2024, then jumped by 48.89% to $429.5 million in 2025, then advanced by 11.39% to $478.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $478.4 million, $429.5 million, and $462.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison